All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Ascendance Biotechnology Inc., of Medford, Mass., said it executed a deal with GE Healthcare, providing Ascendance a right to manufacture, market and sell the GE Healthcare Cytiva brand of human stem cell-derived cardiomyocytes used for evaluating potential cardiotoxicity.